KYTX Kyverna Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1994702 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY2.0%
TTM EPS YoY26.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-110.7%
ROA-83.8%
ROIC (approx.)-105.6%
Asset turnover—
Leverage & solvency
Liabilities / assets29.7%
Debt / equity0.19x
Current ratio7.01x
Interest coverage-64.90x
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $27.02M | $24.79M | $30.07M | $30.01M | $30.46M | $35.82M | $37.43M | $33.48M |
| SG&A expense | $15.88M | $14.77M | $11.29M | $9.27M | $8.27M | $8.59M | $9.97M | $7.56M |
| Operating income | -$42.90M | -$39.56M | -$41.37M | -$39.28M | -$38.73M | -$44.41M | -$47.41M | -$41.04M |
| Interest expense | $728,000 | $674,000 | $667,000 | $444,000 | $7,000 | $14,000 | $25,000 | $27,000 |
| Net income | -$41.94M | -$38.32M | -$39.73M | -$37.80M | -$36.79M | -$42.08M | -$44.63M | -$37.49M |
| EBITDA | -$42.80M | -$39.26M | -$41.02M | -$38.91M | -$38.43M | -$44.11M | -$46.91M | -$40.48M |
| EPS (basic) | -0.68 | -0.63 | -0.66 | — | -0.85 | -0.97 | -1.03 | — |
| EPS (diluted) | -0.68 | -0.63 | -0.66 | — | -0.85 | -0.97 | -1.03 | — |
| Weighted avg. shares (diluted) | 61.96M | 60.90M | 60.43M | — | 43.42M | 43.23M | 43.22M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $31.82M | $31.81M | $32.19M | $124.09M | $34.16M | $53.44M | $56.87M | $96.62M |
| Short-term investments | $138.75M | $167.62M | $204.25M | $155.16M | $136.97M | $158.24M | $185.78M | $189.36M |
| Current assets | $176.26M | $206.54M | $241.73M | $282.95M | $174.93M | $214.33M | $247.65M | $290.60M |
| PP&E, net | $1.36M | $1.33M | $1.34M | $1.55M | $1.79M | $2.16M | $2.44M | $3.35M |
| Total assets | $189.44M | $219.82M | $257.02M | $293.83M | $187.16M | $226.51M | $260.65M | $304.64M |
| Current liabilities | $25.14M | $22.80M | $29.67M | $36.49M | $33.87M | $39.79M | $33.29M | $33.76M |
| Long-term debt | $24.96M | $24.88M | — | $24.74M | — | — | — | — |
| Total debt | $24.96M | $24.88M | — | $24.74M | — | — | — | — |
| Total liabilities | $56.28M | $54.27M | $61.44M | $61.55M | $35.21M | $42.13M | $36.65M | $38.06M |
| Shareholders' equity | $133.15M | $165.55M | $195.58M | $232.28M | $151.95M | $184.38M | $224.01M | $266.59M |
| Net debt | -$6.86M | -$6.92M | — | -$99.35M | — | — | — | — |
| Shares outstanding | 62.54M | 61.57M | 60.53M | 60.39M | 43.79M | 43.24M | 43.22M | 43.21M |
| Cash flow statement | ||||||||
| Operating cash flow | -$35.37M | -$40.31M | -$41.60M | -$33.53M | -$43.32M | -$31.95M | -$44.91M | -$37.06M |
| Capital expenditure | $174,000 | — | — | -$1,000 | $2,000 | $4,000 | $0 | $532,000 |
| Free cash flow | -$35.54M | — | — | -$33.53M | -$43.32M | -$31.95M | -$44.91M | -$37.59M |
| Investing cash flow | $28.52M | $36.13M | -$50.20M | -$17.29M | $22.56M | $29.17M | $5.58M | $29.22M |
| Financing cash flow | $6.86M | $3.79M | -$101,000 | $140.74M | $1.49M | -$649,000 | -$414,000 | -$215,000 |
| Depreciation & amortization | $100,000 | $300,000 | $351,000 | $368,000 | $300,000 | $300,000 | $501,000 | $563,000 |
| Stock-based compensation | $3.62M | $3.51M | $3.17M | $2.70M | $2.70M | $2.52M | $2.16M | $1.38M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.